Cover Image

Unusual Responses to PCSK9 Inhibitors in a Real-world Clinical Cohort

Saved in:

Bibliographic Details
Main Authors:	Bruce A. Warden (Author), Monark N. Nakrani (Author), Carlota Oleaga (Author), Om P. Ganda (Author), P. Barton Duell (Author), Jonathan Q. Purnell (Author), Michael D. Shapiro (Author), Sergio Fazioa (Author)
Format:	Book
Published:	Elsevier, 2020-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol
by: Bruce A. Warden, et al.
Published: (2020)

Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice
by: Bruce A. Warden, et al.
Published: (2021)

Association between Plasma PCSK9 levels and Presence of Coronary Artery Calcium
by: Tahir Mahmood, et al.
Published: (2020)

Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement
by: Bruce A. Warden, et al.
Published: (2021)

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
by: Maya Safarova, et al.
Published: (2024)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023)

A Comprehensive Review of PCSK9 Inhibitors
by: Caroline Coppinger BS, et al.
Published: (2022)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
by: Martin Jozef Péč, et al.
Published: (2023)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
by: Zhen Feng, et al.
Published: (2022)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023)

Sex difference in circulating PCSK9 and its clinical implications
by: Fang Jia, et al.
Published: (2022)

The wind of change - PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
by: Natalia Ilnicka, et al.
Published: (2023)

Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
by: Łukasz Wołowiec, et al.
Published: (2023)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023)

PCSK9 INHIBITORS IN PERIPHERAL ARTERY DISEASE: REVIEW OF EFFICACY, SAFETY, AND OUTCOMES
by: Moiud Mohyeldin
Published: (2024)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
by: Mohsin Haseeb, et al.
Published: (2023)

PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
by: Lin Zhou, et al.
Published: (2024)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
by: A. V. Blokhina, et al.
Published: (2022)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
by: Hye Duck Choi, et al.
Published: (2023)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023)

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017)

The therapeutic effect of PCSK9 inhibitors on dyslipidemia: one-year follow up
by: Maryam Moshkani Farahani, et al.
Published: (2024)

Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
by: Rosaria Vincenza Giglio BD, PhD, et al.
Published: (2023)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022)

The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process - is there a link?
by: Malwina Grobelna, et al.
Published: (2019)

Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study
by: Hailing Liu
Published: (2024)

PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease
by: Natalia Pauli, et al.
Published: (2020)

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study
by: Sehoon Park, et al.
Published: (2023)

PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
by: Elena Dozio, et al.
Published: (2020)

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
by: Fairman KA, et al.
Published: (2017)

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis
by: Yousuf Zafar, et al.
Published: (2020)

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations
by: K Gadkar, et al.
Published: (2014)

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
by: Adorni MP, et al.
Published: (2017)

The E670G SNP in the <it>PCSK9 </it>gene is associated with polygenic hypercholesterolemia in men but not in women
by: Beil Frank U, et al.
Published: (2006)

Inhibitorii PCSK9 - un nou medicament cu efect de reducere a lipidelor
by: Carolina Dumanschi
Published: (2019)

PCSK9 inhibition and broad health outcomes: A Mendelian randomization phenome‑wide association study
by: Kai Zhang, et al.
Published: (2024)

Association study of PCSK9 SNPs (rs505151 & rs562556) and their haplotypes with CVDs in Indian population
by: Kiran Devi, et al.
Published: (2023)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
by: Constantine E Kosmas, et al.
Published: (2017)